Results 261 to 270 of about 376,342 (317)
Some of the next articles are maybe not open access.
Cancers metastatic to the breast
Cancer, 1972During a period of 10 years, 51 patients were found to have metastatic cancer in the breast. There were 44 women and seven men. Eighteen patients had carcinoma, 16 had malignant lymphoma, 14 had malignant melanoma, and three had myosarcomas. It is interesting that 16 of the 51 patients had no prior history of malignant disease—the mammary lesion ...
S I, Hajdu, J A, Urban
openaire +2 more sources
Surgical Clinics of North America, 1999
The unfortunate reality of metastatic breast cancer is that all treatment is palliative in nature. This is a disease that currently has no cure and for which therapy is directed towards accentuating survival and relieving symptoms. Current technology allows the prediction and detection of metastases earlier and with greater accuracy. These achievements
C H, Cha, G D, Kennedy, J E, Niederhuber
openaire +2 more sources
The unfortunate reality of metastatic breast cancer is that all treatment is palliative in nature. This is a disease that currently has no cure and for which therapy is directed towards accentuating survival and relieving symptoms. Current technology allows the prediction and detection of metastases earlier and with greater accuracy. These achievements
C H, Cha, G D, Kennedy, J E, Niederhuber
openaire +2 more sources
Current Opinion in ONCOLOGY, 1993
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Tamoxifen as adjuvant systemic treatment after first isolated locoregional recurrence of breast cancer has been shown to decrease the subsequent locoregional relapse rate, but it affects neither distant metastases nor survival. In metastatic disease, tamoxifen has not improved response when added to ablation of ovarian function. The cyclical sequential
openaire +3 more sources
Current Opinion in Oncology, 1996
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
The management of metastatic breast cancer continues to provide enormous challenges. The taxanes have significant activity in patients with resistant disease, and combination regimens are being evaluated as first-line therapy. The combination of paclitaxel and doxorubicin appears to have substantial activity, but troublesome cardiac toxicity has been ...
openaire +2 more sources
Management of metastatic breast cancer
World Journal of Surgery, 1994AbstractSystemic treatment almost certainly prolongs the median survival of women with metastatic breast cancer, and it may prolong the survival of a small number of patients substantially. Even with conventional therapy, 10% or more patients may live into the second decade after recurrence.
K, Wong, I C, Henderson
openaire +2 more sources
Clinical Orthopaedics and Related Research, 2003
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +2 more sources
Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available
S M, Ali, H A, Harvey, Allan, Lipton
openaire +2 more sources